{"id":"NCT00694109","sponsor":"Kastle Therapeutics, LLC","briefTitle":"An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia","officialTitle":"An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2008-06-10","resultsPosted":"2015-12-21","lastUpdate":"2016-09-09"},"enrollment":144,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lipid Metabolism, Inborn Errors","Hypercholesterolemia, Autosomal Dominant","Hyperlipidemias","Metabolic Diseases","Hyperlipoproteinemia Type II","Metabolism, Inborn Errors","Genetic Diseases, Inborn","Infant, Newborn, Diseases","Metabolic Disorder","Congenital Abnormalities","Hypercholesterolemia","Hyperlipoproteinemias","Dyslipidemias","Lipid Metabolism Disorders"],"interventions":[{"type":"DRUG","name":"Mipomersen Sodium","otherNames":["ISIS 301012","Kynamro®"]}],"arms":[{"label":"Mipomersen","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of extended dosing with mipomersen (ISIS 301012) in participants with familial hypercholesterolemia or severe hypercholesterolemia on lipid-lowering therapy who had completed either the 301012-CS5 (NCT00607373), 301012-CS7 (NCT00706849), 301012-CS17 (NCT00477594) or MIPO3500108 (NCT00794664) clinical drug trials.","primaryOutcome":{"measure":"Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)","timeFrame":"Baseline up to Week 234; 24 weeks post treatment (up to 4.5 years)","effectByArm":[{"arm":"Mipomersen","deltaMin":-28.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":33,"countries":["United States","Brazil","Canada","Singapore","South Africa","Taiwan","United Kingdom"]},"refs":{"pmids":["27578134","24366918"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":141},"commonTop":["Injection site erythema","Injection site pain","Injection site bruising","Influenza like illness","Injection site discolouration"]}}